The Cost-Effectiveness of Primary Prevention Interventions for Skin Cancer: An Updated Systematic Review
- PMID: 38861109
- DOI: 10.1007/s40258-024-00892-2
The Cost-Effectiveness of Primary Prevention Interventions for Skin Cancer: An Updated Systematic Review
Abstract
Objective: Preventing the onset of skin malignancies is feasible by reducing exposure to ultraviolet radiation. We reviewed published economic evaluations of primary prevention initiatives in the past decade, to support investment decisions for skin cancer prevention.
Methods: We assessed cost-effectiveness, cost-utility and benefit-cost analyses published from 1 September 2013. Seven databases were searched on 18 July 2023 and updated on 15 November 2023. Studies must have reported outcomes in terms of monetary costs, life years, quality-adjusted life years or variant thereof. A narrative synthesis was undertaken and reporting quality was assessed by three reviewers using the Consolidated Health Economic Evaluation Reporting Standards checklist.
Results: In total, 12 studies were included with five studies located in Australia; three in North America and the remaining four in Europe. Interventions included restricting the use of indoor tanning devices (7 studies), television advertising, multi-component sun safety campaigns, shade structures plus protective clothing provision for outdoor workers and provision of melanoma genomic risk information to individuals. Most studies constructed Markov cohort models and adopted a societal cost perspective. Overall, the reporting quality of the studies was high. Studies found highly favourable returns on investment ranging from US$0.35 for every $1 spent on prevention, up to €3.60 for every €1 spent. Other studies showed substantial skin cancers avoided, gains in life years, quality-adjusted survival, and societal cost savings.
Conclusions: From both population health and economic perspectives, allocating limited health care resources to primary prevention of skin cancer is highly favourable.
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
References
-
- Arnold M, Singh D, Laversanne M, et al. Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol. 2022;158(5):495–503. https://doi.org/10.1001/jamadermatol.2022.0160 . - PubMed - PMC
-
- Global Cancer Observatory. Cancer Today. 2024. Available at https://gco.iarc.fr/today/home . Accessed 20/04/2024.
-
- Cakir B, Adamson P, Cingi C. Epidemiology and economic burden of nonmelanoma skin cancer. Facial Plast Surg Clin North Am. 2012;20(4):419–22. https://doi.org/10.1016/j.fsc.2012.07.004 . - PubMed
-
- Housman TS, Feldman SR, Williford PM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol. 2003;48(3):425–9. https://doi.org/10.1067/mjd.2003.1186 . - PubMed
-
- Gorry C, McCullagh L, Barry M. Economic evaluation of systemic treatments for advanced melanoma: a systematic review. Value Health. 2020;23(1):52–60. https://doi.org/10.1016/j.jval.2019.1007.1003 . - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
